In FDA trials comparing Mounjaro to other diabetes medications, patients who received the maximum recommended dose of Mounjaro lowered their HbA1c (blood sugar level) by 0.5% more than with semaglutide (brand name: Ozempic) and 1% more than with insulin glargine (a long-acting insulin)
Other side effects included, but are not limited to, minor (NNTH 36, RR: 2.17, 95%CI: 1.38 to 3.43, p = 0.03), symptomatic (NNTH 22, RR: 1.78, 95%CI: 1.15 to 2.74, p = 0.03) hypoglycemic events, dizziness (NNTH 60, RR: 1.39, 95%CI: 1.03 to 1.87, p = 0.04) (Table 5)
While these benefits are promising, its essential to approach glutathione supplementation with a well-informed perspective
The Microdose protocol uses lower initial doses designed to minimize side effects while establishing baseline response